The Effect of Vitamin B17 on Cardiomyopathy against Ehrlich Tumor Development in Female Mice

Document Type : Original Article

Authors

1 Biochemistry Section, Chemistry Department, Faculty of Science, Tanta University, Egypt

2 Department of Clinical Trial Research Unit and Drug Discovery, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.

3 Anatomy and Embryology Department, Faculty of Veterinary Medicine, Kafr El-sheikh University, Egypt.

Abstract

The transplantable tumor model of Ehrlich ascites tumor (EAC), which is a cancer simulation, is frequently used to study the antineoplastic effects of amygdalin (VB17). This study aims to find out how cardiac toxicity and oxidative stress triggered by EAC could be countered with VB17 in female mice. Twenty-five female mice were included and divided into 5 groups namely, the control group (Gp1), EAC (Gp2), VB17 control group (Gp3), EAC+VB17 (Gp4), EAC+VB17+SOR IP (Gp5). All groups underwent cardiac marker assessment in addition to oxidative stress marker MDA determination and the evaluation of the anti-oxidative stress marker of SOD. By comparison with the naïve control group, the EAC positive control group had a significantly higher level of Troponin, serum lactate dehydrogenase (LDH), CK-MB, CPK, and MDA content. On the other hand, the EAC group had significantly lower levels of cardiac SOD than the control group. Furthermore, better improvement in cardiac toxicity and oxidative stress was displayed by the cotreated (VB17+SOR) group 5 than by the (EAC + VB17) group 4. This led to the conclusion that VB17 conferred cardiac protective and antioxidant effects against EAC. This finding necessitates further research into the benefits of VB17 as adjuvant agents in the prevention and treatment of cardiac toxicity.

Keywords

Files

Share

How to cite

Statistics